165 related articles for article (PubMed ID: 31171941)
1. Chimeric antigen receptor T cell therapy for multiple myeloma.
Hasegawa K; Hosen N
Inflamm Regen; 2019; 39():10. PubMed ID: 31171941
[TBL] [Abstract][Full Text] [Related]
2. [Chimeric antigen receptor T-cell therapy for multiple myeloma].
Hosen N
Rinsho Ketsueki; 2018; 59(10):2189-2194. PubMed ID: 30305525
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma.
Hosen N
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31847470
[TBL] [Abstract][Full Text] [Related]
4. [Chimeric antigen receptor T-cell therapy for multiple myeloma].
Hosen N
Rinsho Ketsueki; 2021; 62(6):619-623. PubMed ID: 34219089
[TBL] [Abstract][Full Text] [Related]
5. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy for multiple myeloma.
Hosen N
Int J Hematol; 2020 Apr; 111(4):530-534. PubMed ID: 31981097
[TBL] [Abstract][Full Text] [Related]
7. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
8. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
10. [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells].
Zhong MJ; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):804-811. PubMed ID: 31775477
[No Abstract] [Full Text] [Related]
11. Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
Ding L; Hu Y; Huang H
Stem Cell Investig; 2021; 8():1. PubMed ID: 33575314
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ma T; Shi J; Liu H
Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
[TBL] [Abstract][Full Text] [Related]
13. [Clinical development of CAR-T therapy for refractory multiple myeloma].
Ohmine K
Rinsho Ketsueki; 2018; 59(8):1058-1065. PubMed ID: 30185706
[TBL] [Abstract][Full Text] [Related]
14. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
15. Expression of activated integrin β7 in multiple myeloma patients.
Hosen N; Yoshihara S; Takamatsu H; Ri M; Nagata Y; Kosugi H; Shimomura Y; Hanamura I; Fuji S; Minauchi K; Kuroda J; Suzuki R; Nishimura N; Uoshima N; Nakamae H; Kawano Y; Mizuno I; Gomyo H; Suzuki K; Ozaki S; Nakamura S; Imai Y; Kizaki M; Negoro E; Handa H; Iida S
Int J Hematol; 2021 Jul; 114(1):3-7. PubMed ID: 33999338
[TBL] [Abstract][Full Text] [Related]
16. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.
Roex G; Feys T; Beguin Y; Kerre T; Poiré X; Lewalle P; Vandenberghe P; Bron D; Anguille S
Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32102267
[TBL] [Abstract][Full Text] [Related]
18. BCMA CAR T cells: the winding path to success.
Borrello I; Imus PH
J Clin Invest; 2019 Apr; 129(6):2175-2177. PubMed ID: 31033482
[TBL] [Abstract][Full Text] [Related]
19. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
20. CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth.
Berahovich R; Zhou H; Xu S; Wei Y; Guan J; Guan J; Harto H; Fu S; Yang K; Zhu S; Li L; Wu L; Golubovskaya V
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30208593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
